{"id":"je-cv-vaccine","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions (pain, erythema, swelling)"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL2108573","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine uses a recombinant approach where the Japanese encephalitis virus (JEV) genome is modified to express dengue virus (DENV) structural proteins (prM and E), creating a tetravalent vaccine candidate against all four dengue serotypes while maintaining JEV immunity. This chimeric strategy leverages the established safety profile of the live attenuated JE vaccine platform while expanding protection to dengue, which shares similar transmission vectors and geographic distribution in endemic regions.","oneSentence":"JE-CV is a chimeric vaccine that combines the live attenuated Japanese encephalitis virus backbone with dengue virus structural proteins to provide protection against both Japanese encephalitis and dengue viruses.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:17:34.420Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of Japanese encephalitis and dengue fever in endemic regions"}]},"trialDetails":[{"nctId":"NCT01190228","phase":"PHASE3","title":"Study of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children Previously Immunized With JE-CV","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2010-08-25","conditions":"Japanese Encephalitis, Varicella","enrollment":454},{"nctId":"NCT01001988","phase":"PHASE3","title":"Long-term Follow-up of Immunogenicity of a Single Dose of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2009-08-07","conditions":"Encephalitis, Japanese Encephalitis","enrollment":596},{"nctId":"NCT02602652","phase":"NA","title":"Immunogenicity of a JE-CV as a Booster Dose After a Primary Vaccination With SA14-14-2 Vaccine","status":"COMPLETED","sponsor":"Chulalongkorn University","startDate":"2013-12","conditions":"Japanese Encephalitis","enrollment":50},{"nctId":"NCT00735644","phase":"PHASE3","title":"Study of ChimeriVax™-Japanese Encephalitis Vaccine in Toddlers in Thailand and the Philippines","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2008-08","conditions":"Japanese Encephalitis, Hepatitis A","enrollment":1200},{"nctId":"NCT00621764","phase":"PHASE2","title":"Immunogenicity and Safety of ChimeriVax™ Japanese Encephalitis Vaccine in Thai Toddlers and Children","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2008-03","conditions":"Japanese Encephalitis, Hepatitis A","enrollment":300},{"nctId":"NCT01188343","phase":"PHASE3","title":"Study of Japanese Encephalitis Chimeric Virus Vaccine Given With Measles-Mumps-Rubella Vaccine in Taiwanese Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2010-08","conditions":"Japanese Encephalitis, Measles, Mumps","enrollment":542},{"nctId":"NCT01092507","phase":"PHASE3","title":"A Study of Japanese Encephalitis Chimeric Virus Vaccine Compared With SA14-14-2 Vaccine in Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2010-03","conditions":"Encephalitis, Japanese Encephalitis","enrollment":300},{"nctId":"NCT01954810","phase":"PHASE4","title":"Antibody Response of a Boosted Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children","status":"UNKNOWN","sponsor":"Khon Kaen University","startDate":"2013-10","conditions":"Japanese Encephalitis","enrollment":88},{"nctId":"NCT00441259","phase":"PHASE2","title":"Safety and Efficacy Study of ChimeriVax™-JE and JE Inactivated Mouse Brain Vaccine in Children of Descending Age","status":"COMPLETED","sponsor":"Sanofi","startDate":"2007-01","conditions":"Japanese Encephalitis","enrollment":96}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["IMOJEV"],"phase":"phase_3","status":"active","brandName":"JE-CV Vaccine","genericName":"JE-CV Vaccine","companyName":"Sanofi Pasteur, a Sanofi Company","companyId":"sanofi","modality":"Biologic","firstApprovalDate":"","aiSummary":"JE-CV is a chimeric vaccine that combines the live attenuated Japanese encephalitis virus backbone with dengue virus structural proteins to provide protection against both Japanese encephalitis and dengue viruses. Used for Prevention of Japanese encephalitis and dengue fever in endemic regions.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}